Abstract
Background
ABC classification has been used to assess the risk for gastric cancer. The current problem of ABC classification is that Group A contains individuals with current and past H. pylori infection. The aims of this study were to assesse the proportion of current and past infection in Group A and to establish a criteria for the identification of subjects with past infection from Group A subjects with negative results of urea breath test (UBT) and/or stool antigen test.
Methods
201 subjects classified into Group A received UBT and/or stool antigen test, and also subsequent upper gastrointestinal endoscopy. The subjects were classified by the status of H. pylori infection defined by endoscopic findings. Levels of pepsinogen (PG) I, PG II and PG I/II ratio were compared between the groups, and receiver operating characteristic curves were constructed to extract the corresponding cutoff values.
Results
22 subjects were tested positive by UBT and/or stool antigen test. Endoscopic images of 157 out of 179 subjects were studied. 15 of the subjects were regarded to have past H. pylori infection. The optimal cut-off value of PG I and PG I/II ratio for the determination of past H. pylori infection were ≤ 31.2 ng/mL and ≤ 4.6, respectively.
Conclusions
Approximately 20% of Group A subjects have current or past H. pylori infection. Addition of UBT and/or stool antigen test can identify current but not past infection. Serum PG levels would be useful to identify subjects with past H. pylori infection.
Similar content being viewed by others
References
Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels—“ABC method”. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:405–14.
Matsuo T, Ito M, Takata S, et al. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415–9.
Kudo T, Kakizaki S, Sohara N, et al. Analysis of ABC (D) stratification for screening patients with gastric cancer. World J Gastroenterol. 2011;17:4793–8.
Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer. 2004;109:138–43.
Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.
Miki K, Fujishiro M, Kodashima S, et al. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc. 2009;21:78–81.
Yoshihara M, Hiyama T, Yoshida S, et al. Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case–control study. Scand J Gastroenterol. 2007;42:760–4.
Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis. 2007;8:8–14.
Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006;9:245–53.
Oishi Y, Kiyohara Y, Kubo M, et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol. 2006;163:629–37.
Dinis-Ribeiro M, Yamaki G, Miki K, et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen. 2004;11:141–7.
Urita Y, Hike K, Torii N, et al. Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis. Dig Dis Sci. 2004;49:795–801.
Kiso M, Yoshihara M, Ito M, et al. Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study. Gastric Cancer. 2017;20:764–71.
Kishikawa H, Kimura K, Takarabe S, Kaida S, Nishida J. Helicobacter pylori antibody titer and gastric cancer screening. Dis Markers. 2015. https://doi.org/10.1155/2015/156719.
Kishikawa H, Nishida J, Ichikawa H, et al. Fasting gastric pH of Japanese subjects stratified by IgG concentration against Helicobacter pylori and pepsinogen status. Helicobacter. 2011;16:427–33.
Kawai T, Miki K, Ichinose M, et al. Changes in evaluation of the pepsinogen test result following Helicobacter pylori eradication therapy in Japan. Inflammopharmacology. 2007;15:31–5.
Kawai T, Kawakami K, Kudo T, et al. A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication. Intern Med. 2002;41:780–3.
Ohara S, Kato M, Asaka M, et al. Studies of 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan. J Gastroenterol. 1998;33:6–13.
Sato M, Shimoyama T, Takahashi R, et al. Characterization and usefulness of stool antigen tests using a monoclonal antibody to Helicobacter pylori catalase. J Gastroenterol Hepatol. 2012;27(Suppl 3):23–8.
Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;3:87–97.
Haruma K, Kato M, Inoue K, et al. Kyoto classification of gastritis. 1st ed. Tokyo: Nihon Medical Center; 2017.
Kato T, Yagi N, Kamada T, et al. Study group for establishing endoscopic diagnosis of chronic gastritis diagnosis of Helicobacter pylori infection in gastric mucosa by endoscopic features: a multicenter prospective study. Dig Endosc. 2013;25:508–18.
Iino C, Shimoyama T, Oyama T, et al. Evaluation of the appropriate cut-off value for serological diagnosis of Helicobacter pylori infection by comparison with a stool antigen test. Hirosaki Med J. 2012;63:48–54.
Koizumi W, Tanabe S, Imaizumi H, et al. Effect of anti-Helicobacter pylori IgG antibody titer following eradication of Helicobacter pylori infection. Hepatogastroenterology. 2003;50:293–6.
Marchildon P, Balaban DH, Sue M, et al. Usefulness of serological IgG antibody determinations for confirming eradication of Helicobacter pylori infection. Am J Gastroenterol. 1999;94:2105–8.
Yamaguchi Y, Nagata Y, Hiratsuka R, et al. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels—the ABC method. Digestion. 2016;93:13–8.
Terasawa T, Nishida H, Kato K, et al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. PLoS One. 2014. https://doi.org/10.1371/journal.pone.0109783.
Boda T, Ito M, Yoshihara M, et al. Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm. Helicobacter. 2014;19:1–8.
Ono S, Kato M, Suzuki M, et al. Frequency of Helicobacter pylori -negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion. 2012;86:59–65.
Kakinoki R, Kushima R, Matsubara A, et al. Re-evaluation of histogenesis of gastric carcinomas: a comparative histopathological study between Helicobacter pylori-negative and H. pylori-positive cases. Dig Dis Sci. 2009;54:614–20.
Kato S, Matsukura N, Tsukada K, et al. Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci. 2007;98:790–4.
Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005;54:764–8.
Shimoyama T. Stool antigen tests for the management of Helicobacter pylori infection. World J Gastroenterol. 2013;19:8188–91.
Kishikawa H, Kimura K, Ito A, et al. Cutoff pepsinogen level for predicting unintendedly eradicated cases of Helicobacter pylori infection in subjects with seemingly normal pepsinogen levels. Digestion. 2017;95:229–36.
Yanaoka K, Oka M, Yoshimura N, et al. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int J Cancer. 2008;123:917–26.
Acknowledgements
We gratefully acknowledge the members of The RINGO Study Group. The names of the RINGO study group are as follows: Chinda D, M.D, Ph.D. (author); Shimoyama T, M.D, Ph.D. (author); Sasaki Y, M.D., Ph.D. (author); Komai K, M.D., Ph.D. (author); Sawada Y, M.D., Ph.D. (author); Saito Y, M.D., Ph.D. (author); Chiba H, M.D., Ph.D. (author); Fukuda S, M.D., Ph.D. (author); Akiyama M, M.D., Ph.D.; Ebina T, M.D., Ph.D.; Fukushi G, M.D., Ph.D.; Fukushi M, M.D., Ph.D.; Ichinohe H, M.D., Ph.D.; Ishizawa M, M.D., Ph.D.; Ito J, M.D., Ph.D.; Iwamura H, M.D., Ph.D.; Iwane S, M.D., Ph.D.; Kawaguchi H, M.D., Ph.D.; Kawaguchi S, M.D., Ph.D.; Konuma Y, M.D., Ph.D.; Moriyama Y, M.D., Ph.D.; Nakajima M, M.D., Ph.D.; Nakasato F, M.D., Ph.D.; Nishiya D, M.D., Ph.D.; Okamoto K, M.D., Ph.D.; Soma Y, M.D., Ph.D.; Suzuki H, M.D., Ph.D.; Tomita T, M.D., Ph.D.; Tsushima K, M.D., Ph.D.; Wada T, M.D., Ph.D.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interests regarding the publication of this paper.
Additional information
The members of RINGO Study Group are listed in Acknowledgements.
Rights and permissions
About this article
Cite this article
Chinda, D., Shimoyama, T., Mikami, T. et al. Serum pepsinogen levels indicate the requirement of upper gastrointestinal endoscopy among Group A subjects of ABC classification: a multicenter study. J Gastroenterol 53, 924–931 (2018). https://doi.org/10.1007/s00535-018-1431-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-018-1431-9